Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Adults with overweight or obesity who transitioned from injectable GLP-1 treatments to once-daily oral semaglutide, known as the Wegovy pill, shed an average of 4.1 percent of their body weight after three months. Findings from the OCTANE real-world analysis were presented at the EASD 2026 conference. The results suggest patients may not require lifelong weekly injections and can instead utilize more convenient daily oral treatments. Novo Nordisk also announced a research collaboration with Ro to generate additional real-world evidence for the oral medication, while continuing to present liver-fat and cardiovascular data at the meeting in Milan.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Adults with overweight or obesity who switched from injectable GLP-1 medicines to once-daily oral semaglutide, marketed as the Wegovy pill, lost an average of 4.1 percent of their body weight over three months.
- ✓ The findings were presented as part of the real-world OCTANE analysis at the EASD 2026 conference.
- ✓ Novo Nordisk and Ro announced a research collaboration to generate real-world evidence on the Wegovy pill.
What changed
Real-world study data from the OCTANE trial demonstrates that patients switching from weight-loss injections to the Wegovy pill continue to lose weight.
Live updates
-
Wegovy Pill Shows Weight Loss in Real-World Study
Adults with overweight or obesity who transitioned from injectable GLP-1 treatments to once-daily oral semaglutide, known as the Wegovy pill, shed an average of 4.1 percent of their body weight after three months. Findings from the OCTANE real-world analysis were presented at the EASD 2026 conference. The results suggest patients may not require lifelong weekly injections and can instead utilize more convenient daily oral treatments. Novo Nordisk also announced a research collaboration with Ro to generate additional real-world evidence for the oral medication, while continuing to present liver-fat and cardiovascular data at the meeting in Milan.
Why it matters
The data arrive as drugmakers race to capture market share in the rapidly expanding obesity treatment sector. Novo Nordisk is leaning heavily on oral GLP-1 therapies to bolster growth amid a 24 percent stock slide this year and intense competition from rivals like Eli Lilly. Understanding whether daily pills can maintain or improve weight loss outcomes after injections offers critical direction for long-term patient care strategies.
What is confirmed
- Adults with overweight or obesity who switched from injectable GLP-1 medicines to once-daily oral semaglutide, marketed as the Wegovy pill, lost an average of 4.1 percent of their body weight over three months.
- The findings were presented as part of the real-world OCTANE analysis at the EASD 2026 conference.
- Novo Nordisk and Ro announced a research collaboration to generate real-world evidence on the Wegovy pill.
What to watch next
- Further real-world data releases from the Novo Nordisk and Ro research collaboration.
- Additional long-term weight loss and adherence metrics for patients using oral semaglutide.
confidence 100%Sources used for this update (19)
- Reuters — Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
- CNBC — People switching to Novo's Wegovy pill from obesity injections kept losing weight in real-world study
- qz.com — Switching to Novo Nordisk's weight loss pill helped people keep shedding pounds
- PR Newswire — Ro and Novo Announce Research Collaboration to Generate First-of-its-Kind Real-World Evidence on the Wegovy® Pill
- The Pharma Letter — Real-world study shows continued weight loss after switching to oral Wegovy
- www.ad-hoc-news.de — Novo Nordisk Cuts Wegovy Price in Sweden While Ozempic Data Bests Mounjaro
- www.ad-hoc-news.de — Novo Nordisk Touts Liver-Fat and Cardiovascular Data as It Battles a 24% Slide
- www.devdiscourse.com — Reuters Health News Summary
- www.cnbc.com — Novo's Wegovy pill improves weight loss after switch from ...
- health.yahoo.com — Novo Nordisk Study Reports Weight Loss After Patients Switch ...
- www.prnewswire.com — People switching from weight-loss injections to Novo's Wegovy ...
- www.biopharminternational.com — Wegovy Pill Delivers 4.1% Weight Loss in Patients Switching ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community